Evaluating elevated lipoprotein(a) clinical care impact in an academic health center
Authors:
- Aida RomanARAida Roman
- Shane J. SaccoSSShane J. Sacco
- John G. TiuJTJohn G. Tiu
- 1 July 2026
- journal article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (9) , 1946-1953
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a)American Journal of Preventive Cardiology, 2024
- A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practiceJournal of Clinical Lipidology, 2024
- Lipoprotein(a) Is Markedly More Atherogenic Than LDLJACC, 2024
- Prevalence of lipoprotein(a) measurement in patients with or at risk of cardiovascular diseaseJournal of Clinical Lipidology, 2023
- Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomesAmerican Journal of Preventive Cardiology, 2023
- Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid AssociationJournal of Clinical Lipidology, 2022
- Lipoprotein(a) and its Significance in Cardiovascular DiseaseJAMA Cardiology, 2022
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive SummaryJACC, 2019
- Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General PopulationJACC, 2014
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009